

Curriculum Vitae

Personal information **Pierre Demolis**

Work experience

October 1983-October 1987 House Doctor Assistance Publique Hôpitaux de Paris (France) Physician (Internal medicine, cardiology, nephrology, reanimation)

October 1987-November 1990 University Paris VI, Paris X Senior Registrar Cardiology (France) Physician and Assistant Teacher (cardiology)

November 1990-October 1994 Senior Registrar Clinical Pharmacology University Paris XI/ University Hospital Bicêtre (France) Clinical Trials Ph I/II Physician (cardiology) Assistant Teacher (clinical pharmacology, cardiology)

November 1994-October 2003 Senior Lecturer Clinical Pharmacology University Paris XI/ University Hospital Bicêtre (France) Clinical Trials Ph I/II, Head of Clinical Research Unit (Ph III/IV) Physician (cardiology) Assistant Teacher (clinical pharmacology, cardiology)

November 2003-November 2007 Head Clinical Assessment Unit Oncology Haematology Immunology AFSSaPS (French Medicines Agency) (France)

2004- Present Member Scientific Advice Working Party of the CHMP (EMA) AFSSaPS/ANSM (French Medicines Agency) (France) September

2007-January 2017 Member CHMP (EMA) AFSSaPS/ANSM (French Medicines Agency) (France)

May 2010-October 2016 Vice-Chair OncWP (EMA) AFSSaPS/ANSM (French Medicines Agency) (France)

October 2012-December 2013 Director Oncology Haematology Division ANSM (French Medicines Agency) (France)

October 2013-October 2016 Vice-Chair CHMP (EMA) ANSM (French Medicines Agency)/EMA (France)

December 2013-November 2015 Deputy Director Evaluation Division ANSM (French Medicines Agency) (France)

November 2015-January 2019 Deputy Director Strategy and European Affairs Division ANSM (French Medicines Agency) (France) In charge of European strategy and of coordination between French representations near the EMA.

November 2016-October 2019 Chairman Oncology Working Party of the CHMP (EMA) ANSM (French Medicines Agency) (France)

January 2019- December 2024 Deputy Director, General Direction ANSM (French Medicines Agency) (France) In charge of European strategy and of coordination between French representations near the EMA in the domain of medicines. Medical advisor to the General Directors on alerts with European consequences

January 2025 present Clinical assessor Icelandic Medicines Agency

Education and training

November 1976-September 1983 MD University Paris VI, (France) specialized cardiology, nephrology, internal medicine

November 1990-October 1994 PhD University Paris XI (France) Clinical Pharmacology

October 1992-November 1994 BS University Paris XI/ University Hospital Bicêtre (France) Statistics

Additional information

Publications

- 1 Lang P, Buisson C, Foucher A, Viard JP, Demolis P, Fruchaud G, Benmaadi A, Chopin D, Abbou C. Unusual immune deficiency syndrome associated with LAV/HTLVIII in a kidney transplant recipient. Transplant Proc 1989;18:1400-1401.
- 2 Demolis P, Asmar R, Levy B, Manent PJ, Safar M. Etude non invasive de l'hémodynamique des artères périphériques par échographie bidimensionnelle couplée à un Doppler pulse. Arch Mal Coeur 1990;83:1335-1341.
- 3 Asmar R, Sassano P, Demolis P, Menard J, Safar M. Validation de l'appareil d'automesure de la pression artérielle "Oscillomat". Comparaison au sphygmomanomètre à colonne de mercure. Presse Med 1991;20:551-555.
- 4 Demolis P, Asmar R, Levy B, Safar M. Non invasive evaluation of the conduit function and the buffering function of large arteries in man. Clin Physiol 1991;11:553-554.
- 5 Demolis P, Chalon S, Annane D, Duhaze P, Giudicelli JF. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cerebral blood flow velocities in healthy volunteers. Br J Clin Pharmacol 1992;34:224-230.
- 6 Demolis P, Chalon S, Giudicelli JF. Repeatability of transcranial Doppler measurements of arterial blood flow velocities in healthy volunteers. Clin Sci 1993;84:599-604.
- 7 Demolis P, Carville C, Giudicelli JF. Effects of an angiotensin converting enzyme inhibitor, lisinopril, on cerebral

- blood flow autoregulation in healthy volunteers. *J Cardiovasc Pharmacol* 1993;22:373-380.
- 8 Demolis P, Annane D, Duhaze P, Giudicelli JF. Regional and cerebral hemodynamic effects of a new angiotensin converting enzyme inhibitor, imidapril, in healthy volunteers. *Fundam Clin Pharmacol* 1994;8:80-89.
- 9 Demolis P, Chalon S, Giudicelli JF. Acetazolamide-induced vasodilation in the carotid vascular bed in healthy volunteers. *J Cardiovasc Pharmacol* 1995;26:841-844.
- 10 Demolis P, Tran Dinh YR, Giudicelli JF. Relationships between cerebral regional blood flow velocities and volumetric blood flows and their respective reactivities to acetazolamide. *Stroke* 1996;27:1835-1839. 16/11/2021 European Medicines Agency Page 2/3
- 11 Maison P, Demolis P, Giudicelli JF. Repeatability of Laser Doppler measurements of cutaneous blood flow in healthy volunteers. *Fundam Clin Pharmacol* 1996;10:319-320.
- 12 Chemla D, Demolis P, Thyrault M, Annane D, Lecarpentier Y, Giudicelli JF. Blood flow acceleration in the carotid and brachial arteries of healthy volunteers: respective contributions of cardiac performance and local resistance. *Fundam Clin Pharmacol* 1996;10:393-399.
- 13 Gervais M, Demolis P, Richer C, Giudicelli JF. Systemic and regional haemodynamics assessment in rats with fluorescent microspheres: a validation study. *JCardiovasc Pharmacol* 1999; 33:425-432.
- 14 Demolis P, Florence G, Thomas L, Tran Dinh YR, Giudicelli JF, Seylaz J. Is acetazolamide test valid for quantitative assessment of maximal cerebral autoregulatory vasodilation ? An experimental study in anesthetized rats. *Stroke* 2000;31:508-15.
- 15 Maison P, Demolis P, Young J, Schaison G, Giudicelli JF, Chanson P. Vascular reactivity in acromegalic patients : preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. *Clin Endocrinol* 2000;53 :445-51.
- 16 Demolis P, Antony I, Asmar R, Carette B, Vaisse B. REVEIL trial : Study validity, information and logistics. Preliminary results. Quality measures. *Arch Mal Coeur Vaiss* 2001;94 :901-5.
- 17 Antony I, Asmar R, Carette B, Demolis P, Vaisse B. The REVEIL study: feasibility study of blood pressure self-monitoring. Preliminary results. *Arch Mal Coeur Vaiss* 2001;94 :897-900.
- 18 Lesourd F, Mathieu AM, Ankri J, Pibarot ML, Henry O, Sebbane G, Trivaille Ch, Demolis P, Davrinche P, Guillemot D. Iatrogenie medicamenteuse hospitaliere evitable et personnes agees. *Ann Med Int* 2002;153:13-20.
- 19 Aymard G, Warot D, Demolis P, Laville I, Diquet B. Sensitive determination of nefopam and its metabolite demethyl-nefopam in human biological fluids by HPLC. *J Pharmaceutical Biomed Anal.* 2003; 67:105-9
20. Meurin P, Weber H, Renaud N, Larrazet F, Tabet JY, Demolis P, Ben Driss A. Evolution of the postoperative pericardial effusion after day 15: the problem of the late tamponade. *Chest*.200425(6):2182-7.
21. Mathieu-Boue A, Demolis P, Bergmann JF. Protocolisation, use and development of anti-cancer drugs in the context of T2A (case-mix based payment system) set-up. *Therapie.* 2006 Jul-Aug;61(4):305-12.
22. Leblanc TM, Da Costa L, Marie I, Demolis P, Tchernia G. Metoclopramide treatment in DBA patients: no complete response in a French prospective study. *Blood.* 2007;109(5):2266-7.
23. Trivaille C, Cartier T, Verny C, Mathieu AM, Davrinche P, Agostini H, Becquemont L, Demolis P; IMEPAG GROUP. Identifying and preventing adverse drug events in elderly hospitalised patients: a randomised trial of a program to reduce adverse drug effects. *J Nutr Health Aging.* 2010 Jan;14(1):57-61.
24. Chanson P, Caillex-Bounacer A, Kuhn JM, Weryha G, Chabre O, Borson-Chazot F, Dubois S, Vincent-Dejean C, Brue T, Fedou C, Bresson JL, Demolis P, Souberbielle JC. Comparative Validation of the Growth Hormone-Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency Using a Growth Hormone Assay Conforming to Recent International Recommendations. *J Clin Endocrinol Metab.* 2010 May 19 (5) :624-30.
25. The European Medicines Agency review of cabazitaxel (Jevtana(R)) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use. ean E, Demolis P, Moreau A, Hemmings RJ, O'Connor D, Brown D, Shepard T, Abadie E, Pignatti F. *Oncologist.* 2012;17(4):543-9.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)